Gilead Sciences (NASDAQ: GILD) CEO sells 10,000 shares under 10b5-1 plan

Rhea-AI Filing Summary

Gilead Sciences Chairman & CEO Daniel O'Day reported an open-market sale of 10,000 shares of Common Stock on 2026-03-27 at an average price of $136.8162 per share. The transaction was made under a Rule 10b5-1 trading plan adopted on 2025-02-28, with sale prices ranging from $136.51 to $137.22. Following this sale, he continues to directly hold 642,567 shares of Gilead Sciences common stock.

Insider Trade Summary 10b5-1

Net Seller: 10,000 shares ($1,368,162)

Net Sell 1 txn

Insider O'Day Daniel Patrick

Role Chairman & CEO

Sold 10,000 shs ($1.37M)

Type	Security	Shares	Price	Value
Sale	Common Stock	10,000	$136.8162	$1.37M

Holdings After Transaction: Common Stock — 642,567 shares (Direct)

Footnotes (1)

1. The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025. Sale prices for the transactions reported range from $136.51 to $137.22. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

Key Figures

Shares sold: 10,000 shares Average sale price: $136.8162 per share Post-sale holdings: 642,567 shares +2 more

5 metrics

Shares sold 10,000 shares Open-market sale of Common Stock on 2026-03-27

Average sale price $136.8162 per share Reported average price for 10,000-share sale

Post-sale holdings 642,567 shares Total shares directly owned after the transaction

Sale price range $136.51–$137.22 per share Range of prices for reported sale transactions

Trading plan adoption date 2025-02-28 Rule 10b5-1 trading plan adoption referenced in footnote

Key Terms

Rule 10b5-1 trading plan, open-market sale, Common Stock, Form 4

4 terms

Rule 10b5-1 trading plan regulatory

"The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

""security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

O'Day Daniel Patrick

(Last) (First) (Middle)

333 LAKESIDE DRIVE

(Street)

FOSTER CITY CALIFORNIA 94404

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
GILEAD SCIENCES, INC. [ GILD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chairman & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/27/2026		S(1)		10,000	D	$136.8162(2)	642,567	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025.

2. Sale prices for the transactions reported range from $136.51 to $137.22. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

Remarks:

	/s/ Amy Kim by Power of Attorney for Daniel O'Day	03/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Gilead Sciences (GILD) report for Daniel O'Day?

Gilead Sciences reported that Chairman and CEO Daniel O'Day sold 10,000 shares of Common Stock. The open-market sale occurred on 2026-03-27 at an average price of $136.8162 per share, according to a Form 4 insider trading report.

Was Daniel O'Day's Gilead (GILD) share sale part of a trading plan?

Yes. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on 2025-02-28. Such plans allow insiders to schedule trades in advance, helping separate routine portfolio management from discretionary market-timing decisions.

How many Gilead (GILD) shares did Daniel O'Day sell and at what price range?

Daniel O'Day sold 10,000 Gilead Sciences common shares. The reported sale prices ranged from $136.51 to $137.22 per share, with an average transaction price of $136.8162, as disclosed in the Form 4 insider filing.

How many Gilead Sciences (GILD) shares does Daniel O'Day hold after this sale?

After the 10,000-share sale, Daniel O'Day directly holds 642,567 shares of Gilead Sciences common stock. This figure reflects his remaining direct ownership position reported following the 2026-03-27 transaction on the Form 4.

What type of insider transaction did Gilead (GILD) disclose for its CEO?

The company disclosed an open-market sale of Common Stock by its Chairman and CEO. The Form 4 classifies the transaction with code "S" for sale, indicating a non-derivative disposition of 10,000 shares at an average price of $136.8162 per share.